| |
|
|
|
|
|
|
|||
|
Blood, 7 May 2009, Vol. 113, No. 19, pp. 4604-4613. Prepublished online as a Blood First Edition Paper on February 19, 2009; DOI 10.1182/blood-2008-10-185827.
Submitted October 22, 2008
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States * Corresponding author; email: jaburger{at}mdanderson.org.
Mantle cell lymphoma (MCL) is characterized by an early, widespread dissemination and residual disease after conventional treatment, but the mechanisms responsible for lymphoma cell motility and drug resistance are largely unknown. There is growing evidence suggesting that chemokine receptors and adhesion molecules are critical for malignant B cell trafficking and homing to supportive tissue microenvironments, where they receive survival- and drug resistance-signals. Therefore, we examined chemokine receptor and adhesion molecule expression and function in MCL cells, and their importance for migration and adhesion to marrow stromal cells (MSC). We found that MCL cells display high levels of functional CXCR4 and CXCR5 chemokine receptors and VLA-4 adhesion molecules. We also report that MCL cells adhere and spontaneously migrate beneath MSC in a CXCR4- and VLA-4-dependent fashion (pseudoemperipolesis). Moreover, we demonstrate that MSC confer drug resistance to MCL cells, particularly to MCL cells that migrate beneath MSC. To target MCL-MSC interactions, we tested Plerixafor, a CXCR4 antagonist, and Natalizumab, a VLA-4 antibody. Both agents blocked functional responses to the respective ligands, and inhibited adhesive interactions between MCL cells and MSC. These findings provide a rationale to further investigate the therapeutic potential of these drugs in MCL.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2009 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||